Skip to content

Awareness and Self-Compassion Enhancing Narcolepsy Treatment

Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04306952
Acronym
ASCENT
Enrollment
60
Registered
2020-03-13
Start date
2020-06-15
Completion date
2022-06-30
Last updated
2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy

Keywords

Narcolepsy, psychosocial, mindfulness, health-related quality of life, hypersomnia

Brief summary

The overall goal of this research is to test the effectiveness of a mindfulness-based intervention (MBI) for improving health-related quality of life as a complementary practice to standard care for narcolepsy. This study is a feasibility trial in which 60 adults with narcolepsy will be randomized to receive either a 4-week (brief), 8-week (standard), or 12-week (extended) MBI. Each MBI will be delivered in small groups using a live videoconferencing platform and teaches mindfulness practices to help cope with narcolepsy symptoms. By developing a scalable mind-body intervention, this project can addresses a major research gap on improving psychosocial functioning in people with narcolepsy.

Detailed description

Narcolepsy is a serious and debilitating condition involving persistent and excessive sleepiness that affects 1 in 2000 Americans and 3 million people worldwide. Although wake-promoting pharmacotherapy can reduce sleepiness there is no cure and people with narcolepsy experience significantly poor health-related quality of life, particularly in the domains of mental and social health. Therefore, the overarching goal of this research is to test the effectiveness of a mindfulness-based intervention (MBI) for improving health-related quality of life as a complementary practice to standard care for narcolepsy. The purpose of this study is to conduct a feasibility trial to determine the optimal parameters for adapting and delivering MBI to people with narcolepsy. The specific aims are to: 1) Determine the feasibility and acceptability of MBI delivered using videoconferencing for the purpose of improving psychosocial functioning in people with narcolepsy and 2) Determine the feasibility of recruitment and assessment methods for delivering MBI using videoconferencing. The feasibility trial includes 60 adults with narcolepsy who will be randomized to receive either a 4-week (brief), 8-week (standard), or 12-week (extended) MBI. Each MBI will be similar in content, which includes mindfulness practices and group discussions with adaptations for working with narcolepsy symptoms. All MBIs will be delivered in small groups using a live videoconferencing platform to enhance accessibility. If the findings of this project support the feasibility of further testing, the next project would be aimed at enhancing rigor and reproducibility (e.g., designing appropriate control, refining outcome measures and eligibility criteria) in preparation for a large-scale pragmatic trial. The overall significance of this research is to develop a scalable mind-body intervention that addresses a major research gap on improving psychosocial functioning in people with narcolepsy.

Interventions

BEHAVIORALBrief MBI

The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.

BEHAVIORALStandard MBI

The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.

BEHAVIORALExtended MBI

The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours).

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants are assigned to receive one of there different MBI treatments: 1) Brief MBI, 4 weeks, 2) Standard MBI, 8 weeks, 3) Extended MBI, 12 weeks

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Males and females age 18 and older (except when the age of majority for a state differs from 18, including Delaware \[19 years or older\], Mississippi \[21 years or older\], and Nebraska \[19 years or older\]) 2. ICSD-3 criteria (8) for Narcolepsy (Type I or II) 3. Endorse current psychological distress based on a t-score ≥ 60 on the PROMIS depression or anxiety scales 4. Established standard care for narcolepsy. Patients who have not been previously diagnosed will be required to complete a clinical work-up through a sleep clinic (i.e., nocturnal PSG followed by a next-day MSLT) before participating. Standard care is managed outside of the study.

Exclusion criteria

1. Hypersomnia not of central origin (i.e., hypersomnia attributed to psychiatric disorder, medical disorder, other sleep disorder such as circadian rhythm sleep disorder, or insufficient sleep). 2. Current suicidal ideation or intent. 3. Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol. 4. Inability to engage in the treatment protocol due to a psychiatric (e.g., psychotic disorder) or cognitive issue. 5. Untreated moderate-to-severe sleep-related breathing disorder, defined as an apnea hypopnea index (AHI) ≥ 15. Those receiving treatment for a sleep-related breathing disorder and can demonstrate adequate management (e.g., residual AHI \< 5) will be allowed to participate. 6. Previous participation in a formal MBI program, such as MBSR. 7. Unstable dose of medications at the time of screening (e.g., stimulants). 8. Unable to attend intervention sessions due to accessibility (i.e., reliable internet connection) or availability (i.e., not available due to scheduling conflicts). 9. Currently living outside of the United States.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Attended ≥ 80% of Sessions4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)Number of participants who attended greater than or equal to 80% of sessions
Number of Participants Who Practiced Meditation ≥ 4 Days Per Week4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)Number of participants who practiced meditation greater than or equal to 4 days per week
Number of Participants Who Completed AssessmentsBaseline and 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)Number of participants who completed entire baseline and post-treatment assessment (questionnaires, actigraphy, and neurocognitive testing)

Secondary

MeasureTime frameDescription
Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScaleBaseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)Measures the direct negative psychosocial effect related to illness with higher scores reflecting worse outcomes. Population mean (T-score) of 50 with a standard deviation of 10.
Patient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleBaseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)Measures overall physical and mental health with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10.
Self-Compassion Scale (SCS)Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)The SCS assesses the acquisition of self-compassion. It is a 26-item self report measure with three main components of self-compassion: self-kindness vs. self-judgement, common humanity vs. isolation, and mindfulness vs. over-identification. The total score ranges from 1-5, with higher scores reflecting more self-compassion.
Patient Reported Outcomes Measurement Information System (PROMIS) Depression ScaleBaseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more depressive symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10.
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScaleBaseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10.
Five Facet Mindfulness Questionnaire (FFMQ)Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)The FFMQ assesses the acquisition of mindfulness skills. It is a 39-item self-report measure that consists of five factors representing elements of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience. Total scores range from 39-195, with higher scores reflecting more mindfulness.
Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositiveBaseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)Measures the direct positive psychosocial effect related to illness with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10.

Countries

United States

Participant flow

Participants by arm

ArmCount
Brief MBI
The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. Brief MBI: The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
20
Standard MBI
The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. Standard MBI: The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
20
Extended MBI
The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional office hoursin between the bi-weekly group sessions and one all day meditation retreat. Extended MBI: The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours).
20
Total60

Baseline characteristics

CharacteristicBrief MBIStandard MBIExtended MBITotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants1 Participants2 Participants3 Participants
Age, Categorical
Between 18 and 65 years
20 Participants19 Participants18 Participants57 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants2 Participants2 Participants6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants18 Participants18 Participants54 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Patient-Reported Outcomes Measurement Information System Depression59.53 T-Score
STANDARD_DEVIATION 4.76
56.11 T-Score
STANDARD_DEVIATION 4.81
60.06 T-Score
STANDARD_DEVIATION 6.25
58.57 T-Score
STANDARD_DEVIATION 5.52
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants2 Participants3 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
18 Participants20 Participants17 Participants55 Participants
Sex/Gender, Customized
Female
16 Participants17 Participants20 Participants53 Participants
Sex/Gender, Customized
Male
3 Participants2 Participants0 Participants5 Participants
Sex/Gender, Customized
Non-binary
1 Participants1 Participants0 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 200 / 20
other
Total, other adverse events
7 / 205 / 201 / 20
serious
Total, serious adverse events
0 / 201 / 200 / 20

Outcome results

Primary

Number of Participants Who Attended ≥ 80% of Sessions

Number of participants who attended greater than or equal to 80% of sessions

Time frame: 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Brief MBINumber of Participants Who Attended ≥ 80% of Sessions15 Participants
Standard MBINumber of Participants Who Attended ≥ 80% of Sessions13 Participants
Extended MBINumber of Participants Who Attended ≥ 80% of Sessions15 Participants
Primary

Number of Participants Who Completed Assessments

Number of participants who completed entire baseline and post-treatment assessment (questionnaires, actigraphy, and neurocognitive testing)

Time frame: Baseline and 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Brief MBINumber of Participants Who Completed Assessments18 Participants
Standard MBINumber of Participants Who Completed Assessments13 Participants
Extended MBINumber of Participants Who Completed Assessments16 Participants
Primary

Number of Participants Who Practiced Meditation ≥ 4 Days Per Week

Number of participants who practiced meditation greater than or equal to 4 days per week

Time frame: 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Brief MBINumber of Participants Who Practiced Meditation ≥ 4 Days Per Week16 Participants
Standard MBINumber of Participants Who Practiced Meditation ≥ 4 Days Per Week8 Participants
Extended MBINumber of Participants Who Practiced Meditation ≥ 4 Days Per Week13 Participants
Secondary

Five Facet Mindfulness Questionnaire (FFMQ)

The FFMQ assesses the acquisition of mindfulness skills. It is a 39-item self-report measure that consists of five factors representing elements of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience. Total scores range from 39-195, with higher scores reflecting more mindfulness.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBIFive Facet Mindfulness Questionnaire (FFMQ)Baseline115.90 score on a scaleStandard Deviation 24.8
Brief MBIFive Facet Mindfulness Questionnaire (FFMQ)Post-treatment132.42 score on a scaleStandard Deviation 21.91
Standard MBIFive Facet Mindfulness Questionnaire (FFMQ)Baseline122.50 score on a scaleStandard Deviation 22.13
Standard MBIFive Facet Mindfulness Questionnaire (FFMQ)Post-treatment144.00 score on a scaleStandard Deviation 16.11
Extended MBIFive Facet Mindfulness Questionnaire (FFMQ)Baseline107.00 score on a scaleStandard Deviation 13.43
Extended MBIFive Facet Mindfulness Questionnaire (FFMQ)Post-treatment136.53 score on a scaleStandard Deviation 19.42
Secondary

Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale

Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScaleBaseline62.54 T-scoreStandard Deviation 7.04
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScalePost-treatment62.46 T-scoreStandard Deviation 9.79
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScaleBaseline61.24 T-scoreStandard Deviation 4.85
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScalePost-treatment56.62 T-scoreStandard Deviation 6.25
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScaleBaseline61.69 T-scoreStandard Deviation 6.67
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Anxiety ScalePost-treatment58.04 T-scoreStandard Deviation 7.48
Secondary

Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale

Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more depressive symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Depression ScaleBaseline59.53 T-scoreStandard Deviation 4.76
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Depression ScalePost-treatment57.70 T-scoreStandard Deviation 9.08
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Depression ScaleBaseline56.11 T-scoreStandard Deviation 4.81
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Depression ScalePost-treatment53.89 T-scoreStandard Deviation 6.3
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Depression ScaleBaseline60.06 T-scoreStandard Deviation 6.25
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Depression ScalePost-treatment52.73 T-scoreStandard Deviation 6.08
Secondary

Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale

Measures overall physical and mental health with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Mental Health (Baseline)38.01 T-scoreStandard Deviation 7.89
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Mental Health (Post-treatment)41.17 T-scoreStandard Deviation 10.09
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Physical Health (Baseline)46.32 T-scoreStandard Deviation 7.46
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Physical Health (Post-treatment)47.41 T-scoreStandard Deviation 8.16
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Physical Health (Post-treatment)46.32 T-scoreStandard Deviation 6.82
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Mental Health (Baseline)40.43 T-scoreStandard Deviation 6.07
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Physical Health (Baseline)43.85 T-scoreStandard Deviation 6.15
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Mental Health (Post-treatment)44.77 T-scoreStandard Deviation 7.35
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Physical Health (Post-treatment)45.12 T-scoreStandard Deviation 8.32
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Mental Health (Post-treatment)42.73 T-scoreStandard Deviation 8.09
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Physical Health (Baseline)43.71 T-scoreStandard Deviation 6.44
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Global Health ScaleGlobal Mental Health (Baseline)36.03 T-scoreStandard Deviation 7.82
Secondary

Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale

Measures the direct negative psychosocial effect related to illness with higher scores reflecting worse outcomes. Population mean (T-score) of 50 with a standard deviation of 10.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScaleBaseline60.94 T-scoreStandard Deviation 6.53
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScalePost-treatment58.70 T-scoreStandard Deviation 10.09
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScaleBaseline59.35 T-scoreStandard Deviation 5.28
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScalePost-treatment56.52 T-scoreStandard Deviation 6.24
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScaleBaseline62.59 T-scoreStandard Deviation 8.26
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative ScalePost-treatment57.28 T-scoreStandard Deviation 6.75
Secondary

Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive

Measures the direct positive psychosocial effect related to illness with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositiveBaseline39.35 T-scoreStandard Deviation 8
Brief MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositivePost-treatment42.83 T-scoreStandard Deviation 8.92
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositiveBaseline42.07 T-scoreStandard Deviation 6.84
Standard MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositivePost-treatment46.94 T-scoreStandard Deviation 8.26
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositiveBaseline38.74 T-scoreStandard Deviation 7.23
Extended MBIPatient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact PositivePost-treatment43.85 T-scoreStandard Deviation 9.02
Secondary

Self-Compassion Scale (SCS)

The SCS assesses the acquisition of self-compassion. It is a 26-item self report measure with three main components of self-compassion: self-kindness vs. self-judgement, common humanity vs. isolation, and mindfulness vs. over-identification. The total score ranges from 1-5, with higher scores reflecting more self-compassion.

Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)

Population: Post-treatment scores not available for participants who did not complete the assessment

ArmMeasureGroupValue (MEAN)Dispersion
Brief MBISelf-Compassion Scale (SCS)Baseline2.66 score on a scaleStandard Deviation 0.8
Brief MBISelf-Compassion Scale (SCS)Post-treatment3.12 score on a scaleStandard Deviation 0.86
Standard MBISelf-Compassion Scale (SCS)Baseline2.91 score on a scaleStandard Deviation 0.82
Standard MBISelf-Compassion Scale (SCS)Post-treatment3.58 score on a scaleStandard Deviation 0.58
Extended MBISelf-Compassion Scale (SCS)Baseline2.52 score on a scaleStandard Deviation 0.5
Extended MBISelf-Compassion Scale (SCS)Post-treatment3.61 score on a scaleStandard Deviation 0.61

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026